Sino Biopharmaceutical company profile
Company profile
Sino Biopharmaceutical has 22,838 employees and is headquartered in Wan Chai, Hong Kong.
Based in Wan Chai, Hong Kong, and incorporated in 2000, Sino Biopharmaceutical Limited is an investment holding company whose operations centre on the research, development and sale of pharmaceuticals in the People's Republic of China. The group reports through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. Its oncology range includes anlotinib hydrochloride capsules under the Focus V brand, penpulimab injection under Annike and zongertinib tablets under Hernexeos, alongside liver disease treatments such as Tianqing Ganmei and Runzhong products, respiratory medicines and surgery and analgesia drugs. The company also holds long-term investments and runs a healthcare and hospital business.
In the fiscal year ended December 2025, the company recorded revenue of CNY 31.8 billion, up 10.3% from the previous year, and a net profit of CNY 2.3 billion. It had 22,838 employees, and its headquarters are in Wan Chai, Hong Kong.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Hong Kong SAR China
- Headquarters
- Unit 09, Office Tower, Wan Chai
- Employees
- 22,838
- Chief executive
- S. Y. Tse
- Founded
- 2000
- Fiscal year
- January - December
- Listing
- 1177 · HKEX
- Indices
- Hang Seng
- Currency
- HKD
- ISIN
- KYG8167W1380
- Website
- sbpgroup.com
Sino Biopharmaceutical and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Sino Biopharmaceutical1177 | Hong Kong SAR China | $11.65B | 22,838 | 28.2% | 34.2 |
| Pharmaron Beijing300759 | China | $10.59B | 25,088 | 14.0% | 39.3 |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | Hong Kong SAR China | $12.15B | 2,300 | -0.2% | — |
| ALTEOGEN196170 | South Korea | $9.05B | 181 | 47.2% | 97.1 |
| Haisco Pharmaceutical Group002653 | China | $8.97B | 5,597 | 21.1% | 44.1 |
| Genscript Biotech1548 | Hong Kong SAR China | $8.77B | 6,135 | 14.9% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
